Dounya Schoormans

Dounya Schoormans

Auto-generated profile, based on publicly available information

Dounya Schoormans

Affiliations Department of Medical and Clinical Psychology, CoRPS - Center of Research on Psychological disorders and Somatic diseases, Tilburg University, Tilburg, The Netherlands, Department of Research, Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, The Netherlands

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 August 2021 in Cancer
Verified
Journal Article
Open access
PDF file
BRBelle H. de Rooij
Belle H. de Rooij
SOSimone Oerlemans
Simone Oerlemans
KDKatrijn van Deun
Katrijn van Deun
FMFloortje Mols
Floortje Mols
KLKelly M. de Ligt
Kelly M. de Ligt
DSDounya Schoormans
Dounya Schoormans
Background: Research into the clustering of symptoms may improve the understanding of the underlying mechanisms that affect survivors' symptom burden. This study applied network analyses in a balanced sample of cancer survivors to 1) explore the clustering of symptoms and 2) assess differences in symptom clustering between cancer types, treatment regimens, and short‐term and long‐term survivors.Methods: This study used cross‐sectional survey data, collected between 2008 and 2018, from the population‐based Patient Reported Outcomes Following Initial Treatment and Long Term Evaluation of Survivorship registry, which included survivors of 7 cancer types (colorectal cancer, breast cancer, ovarian cancer, thyroid cancer, chronic lymphocytic leukemia, Hodgkin lymphoma, and non‐Hodgkin lymphoma). Regularized partial correlation network analysis was used to explore and visualize the associations between self‐reported symptoms (European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire) and the centrality of these symptoms in the network (ie, how strongly a symptom was connected to other symptoms) for the total sample and for subgroups separately.Results: In the total sample (n = 1330), fatigue was the most central symptom in the network with moderate direct relationships with emotional symptoms, cognitive symptoms, appetite loss, dyspnea, and pain. These relationships persisted after adjustments for sociodemographic and clinical characteristics. Connections between fatigue and emotional symptoms, appetite loss, dyspnea, and pain were consistently found across all cancer types (190 for each), treatment regimens, and short‐term and long‐term survivors.Conclusions: In a heterogenous sample of cancer survivors, fatigue was consistently the most central symptom in all networks. Although longitudinal data are needed to build a case for the causal nature of these symptoms, cancer survivorship rehabilitation programs could focus on fatigue to reduce the overall symptom burden.

15 September 2018 in Cancer Medicine
Verified
Journal Article
Open access
PDF file
DSDounya Schoormans
Dounya Schoormans
PVPauline A. J. Vissers
Pauline A. J. Vissers
MHMyrthe P. P. van Herk‐Sukel
Myrthe P. P. van Herk‐Sukel
JDJohan Denollet
Johan Denollet
SPSusanne S. Pedersen
Susanne S. Pedersen
LPLonneke van de Poll‐Franse
Lonneke van de Poll‐Franse
We examined the incidence of cardiovascular disease ( CVD ) among 32 757 cancer survivors and age‐, gender‐, and geographically matched cancer‐free controls during a follow‐up period of 1‐13 years, and explored whether CVD incidence differed by received cancer treatment, traditional cardiovascular risk factors, age, or gender. Adult 1‐year cancer survivors without a history of CVD diagnosed with breast (n = 6762), prostate (n = 4504), non‐Hodgkin (n = 1553), Hodgkin (n = 173), lung and trachea (n = 2661), basal cell carcinoma ( BCC ; n = 12 476), and colorectal (n = 4628) cancer during 1999‐2011 were selected from the Netherlands Cancer Registry and matched to cancer‐free controls without a history of CVD . Drug dispenses and hospitalizations from the PHARMO Database Network were used as proxy for CVD . Data were analyzed using Cox regression analyses. Prostate ( HR : 1.17; 95% CI : 1.01‐1.35) and lung and trachea ( HR : 1.48; 95% CI : 1.10‐1.97) cancer survivors had an increased risk for developing CVD compared to cancer‐free controls. This increased risk among lung and trachea cancer survivors remained statistically significant after including traditional cardiovascular risk factors and cancer treatment information ( HR : 1.41; 95% CI : 1.06‐1.89). Among prostate cancer survivors, the increased risk of incident CVD was limited to those who received hormones and those without traditional cardiovascular risk factors. Breast, non‐Hodgkin, BCC , and colorectal cancer survivors showed no increased CVD risk compared to cancer‐free controls. There was an increased risk of incident CVD among prostate, and lung and trachea cancer survivors compared to age‐, gender‐ and geographically matched cancer‐free controls. Studies including longer follow‐up periods are warranted to examine whether cancer survivors are at increased risk of long‐term incident CVD .

3 June 2020 in Head & Neck
Verified
Journal Article
Open access
PDF file
DSDounya Schoormans
Dounya Schoormans
LWLaura Wijnberg
Laura Wijnberg
HHHarm Haak
Harm Haak
Olga HussonOlga Husson
Olga Husson
FMFloortje Mols
Floortje Mols
Background: Differentiated thyroid cancer (DTC) reports a poorer health‐related quality of life (HRQoL) than a norm population. Patients' illness perceptions are modifiable and known associates of HRQoL in other cancers. The aim was to examine the relationship between illness perceptions and HRQoL among DTC survivors.Methods: DTC survivors registered in the Netherlands Cancer Registry diagnosed between 1990 and 2008, received a survey on illness perceptions (Brief‐Illness Perception Questionnaire; B‐IPQ) and HRQoL (European Organisation for Research and Treatment of Cancer, Quality of Life Questionnaire‐Core 30; EORTC QLQ‐C30). Multiple regression analyses were conducted investigating the relation between illness perceptions and HRQoL, while controlling for sociodemographic and clinical characteristics.Results: Two hundred and eighty‐four DTC survivors were included. DTC survivors who believed their illness had many negative consequences; who perceived their illness as controllable by treatment; who had strong beliefs symptoms could be attributed to their illness; and who had strong beliefs their illness causes negative emotions, reported a poorer HRQoL.Conclusions: Stronger negative illness perceptions are related to a poorer HRQoL among DTC survivors.

24 February 2022 in JNCI: Journal of the National Cancer Institute
Verified
Journal Article
Open access
PDF file
LPLonneke V van de Poll-Franse
Lonneke V van de Poll-Franse
NHNicole Horevoorts
Nicole Horevoorts
DSDounya Schoormans
Dounya Schoormans
SBSandra Beijer
Sandra Beijer
NENicole P M Ezendam
Nicole P M Ezendam
JRJanneke van Roij
Janneke van Roij
To take cancer survivorship research to the next level, it’s important to gain insight in trajectories of changing patient-reported outcomes and impaired recovery after cancer. This is needed as the number of survivors is increasing and a large proportion is confronted with changing health after treatment. Mechanistic research can facilitate the development of personalized risk-stratified follow-up care and tailored interventions to promote healthy cancer survivorship. We describe how these trajectories can be studied by taking the recently extended Dutch population-based Patient Reported Outcomes Following Initial treatment and Long term Evaluation of Survivorship (PROFILES) registry as an example. PROFILES combines longitudinal assessment of patient-reported outcomes with novel, ambulatory and objective measures (eg, activity trackers, blood draws, hair samples, online food diaries, online cognitive tests, weighing scales, online symptoms assessment), and cancer registry and pharmacy databases. Furthermore, we discuss methods to optimize the use of a multidomain data collection–like return of individual results to participants, which may improve not only patient empowerment but also long-term cohort retention. Also, advanced statistical methods are needed to handle high-dimensional longitudinal data (with missing values) and provide insight into trajectories of changing patient-reported outcomes after cancer. Our coded data can be used by academic researchers around the world. Registries like PROFILES, which go beyond boundaries of disciplines and institutions, will contribute to better predictions of who will experience changes and why. This is needed to prevent and mitigate long-term and late effects of cancer treatment and to identify new interventions to promote health.

17 March 2021 in Journal of Cancer Survivorship
Verified
Journal Article
Closed access
PDF file
SOSimone Oerlemans
Simone Oerlemans
SSSanne B. Schagen
Sanne B. Schagen
CHCorina van den Hurk
Corina van den Hurk
Olga HussonOlga Husson
Olga Husson
DSDounya Schoormans
Dounya Schoormans
LPLonneke V. van de Poll-Franse
Lonneke V. van de Poll-Franse